{"title":"Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4 -amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3 -amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole","authors":"C.P. Coyne","doi":"10.17303/jcrto.2013.2.203","DOIUrl":"https://doi.org/10.17303/jcrto.2013.2.203","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73247334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immunomodulatory Response Triggered by the Alkaloids, 3-Amino7-Benzylbenzimidazo[3,2-a] Quinolinium Chloride (ABQ-48) and 3-Nitro7-Benzylbenzimidazo[3,2-a] Quinolinium Chloride (NBQ-48)","authors":"B. Zayas","doi":"10.17303/jcrto.2013.3.103","DOIUrl":"https://doi.org/10.17303/jcrto.2013.3.103","url":null,"abstract":"","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91262704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Epicholesteryl Betulinate and the Pegylated 3’ α-Cholesteryl Betulinate are Active Against Liver Carcinoma. A Case Study.","authors":"E. Couché, M. Gelbcke, A. Burny, J. Leunis","doi":"10.17303/jcrto.2019.7.203","DOIUrl":"https://doi.org/10.17303/jcrto.2019.7.203","url":null,"abstract":"The Epicholesteryl Betulinate and the Pegylated 3’ α-Cholesteryl Betulinate are Active Against Liver Carcinoma. A Case Study. E. Couché 1, M. Gelbcke 2, A. Burny 3 and J.C.Leunis4,* 1Ecole Européenne de Luxembourg,Blv Konrad Adenauer 23, L-1115 Luxembourg 2Faculty of Pharmacy, ULB, Free University of Brussels 3Molecular and Cellular Biology, University of Liège 4Jean Monnet Research Center 1, Jean Monnet Avenue B 1348, Louvain-la-Neuve Casereport Open Access Journal of Cancer Research and Therapeutic Oncology","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78732677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Safety Issues of Biosimilar Products","authors":"Abdul Kader Mohiuddin","doi":"10.23880/ACT-16000158","DOIUrl":"https://doi.org/10.23880/ACT-16000158","url":null,"abstract":"Biologics are complex molecules that are manufactured using living cells and used in the treatment of several chronic inflammatory diseases and cancer [1]. As biosimilars offer the potential for lower acquisition costs versus the originator biologic, evaluating the economic implications of the introduction of biosimilars is of interest [2]. As the costs of biologics are high, biosimilars offer the potential of greater choice and value, increased patient access to treatment, and the potential for improved outcomes [3]. By providing more-affordable treatment options and introducing price competition to the market, biosimilar medicines can generate significant savings. The cumulative savings between 2016 and 2020 in the EU5 and the USA are estimated to range between 49 billion Euros and 98 billion Euros [4]. The Biologics Price Competition and Innovation Act (BPCIA) grants 12 years of exclusivity to originator or reference biologics; therefore, by law, the FDA cannot approve a biosimilar until this period has elapsed [2,5]. Patents for many branded biologics will expire during the next few years, allowing biosimilars manufacturers to seek FDA approval for generic versions of these agents [2]. The Biologics Price Competition and Innovation Act (BPCIA), which is part of the patient protection and affordable care act, were passed to facilitate the entry of biosimilar drugs into the market [6]. There has been an increasing trend toward the approval of biosimilars in the USA and the EU. The original goal of legislation to approve biosimilars through a fast-track process that would lead to more competition and price reductions is starting to be realized [7]. According to the BPCIA, a biologic product is deemed biosimilar to the already approved, originator biologic if the available data show that it is highly similar to the reference product, “notwithstanding minor differences in clinically inactive components, and there are no clinically significant differences between the biologic product and the reference product in terms of safety, purity, and potency of the product” [8-10]. Approval of biosimilars requires comprehensive assessment of all stages of the research and development process, including evaluation of analytical, preclinical and clinical data, to establish bio-similarity to their reference products. The goal of biosimilar comparability studies is not to re-establish efficacy and safety for the proposed biosimilar, but to demonstrate similarity to the reference product [11,12]. The biosimilar development pathway consists of a comprehensive comparability exercise between the biosimilar candidate and the reference product, primarily focusing on data from analytical studies. Clinical studies for biosimilar candidates follow a different design to those for a new biological, as the aim is not to independently establish clinical benefit, but to confirm bio-similarity between the two agents [4]. Physician awareness and perceptions towards biosimilars ","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76240858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Sugimoto, H. Kuroda, Yasumishi Kuwahara, Yoshiki Katsumi, A. Misawa, Hiroshi, Moritake, H. Hosoi
{"title":"Cellular and Molecular Characteristics of Established Childhood Soft-Tissue Sarcoma Cell Lines","authors":"T. Sugimoto, H. Kuroda, Yasumishi Kuwahara, Yoshiki Katsumi, A. Misawa, Hiroshi, Moritake, H. Hosoi","doi":"10.17303/jcrto.2019.7.202","DOIUrl":"https://doi.org/10.17303/jcrto.2019.7.202","url":null,"abstract":"From 1984 to 2013, we established 29 childhood tumor cell lines, including 13 soft-tissue-sarcoma cell lines. Here, we provide an overview of these soft-tissue sarcoma cell lines, their origins, characteristics, and highlight their potential as valuable research tools for fundamental research and development of new treatments. The cell lines were established from three patients with rhabdomyosarcoma (RMS), five patients with Ewing sarcoma family tumors, four patients with rhabdoid tumors, and one patient with clear cell sarcoma of soft parts. In particular, we demonstrate the potential of the MRT cell lines in preclinical in vivo and in vitro studies to evaluate molecular target therapy using gefitinib and trastuzumab activated antibody-dependent cellular cytotoxicity. Moreover, the clear cell sarcoma cell line, MP-CCS-SY, was established from a metastatic tumor in the left Achilles tendon of a 17-year-old girl, which represents a rare cell line for this cancer, and will help to gain a better understanding of the molecular biology of this malignancy and serve as a useful tool for developing boron neutron capture therapy.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89484636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Addie Hill, Mihaela Cristea, Miaoling He, Paul Frankel, Susan Neuhausen, Sumanta K Pal, Jeremy O Jones
{"title":"Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer.","authors":"Addie Hill, Mihaela Cristea, Miaoling He, Paul Frankel, Susan Neuhausen, Sumanta K Pal, Jeremy O Jones","doi":"10.17303/jcrto.2019.7.103","DOIUrl":"https://doi.org/10.17303/jcrto.2019.7.103","url":null,"abstract":"<p><p>We sought to evaluate androgen receptor (AR) and PI3K pathway activity in ovarian cancer cell lines and tissue and determine if either pathway was correlated with growth of ovarian cancers. AR expression and activity were quantified using immunohistochemistry (IHC) and RT-qPCR in six ovarian cancer cell lines and 51 tissue samples. Phospho-mTOR and AKT expression were quantified by IHC as well. Cell growth was assessed in the presence of AR modulating drugs and metformin. We found that despite robust AR expression and activity, no cell line was dependent on androgen for growth. However, metformin inhibited activity in five of the six cell lines. Patient tissues had large variation in AR expression and activity, as well as in expression of phospho-mTOR and AKT, but none of these variables correlated with progression-free survival (PFS). AR expression and activity did not predict the dependence of ovarian cancer cell lines on androgens for growth, and AR expression and activity did not correlate with PFS. This result suggests that AR expression as a criterion for patient selection for clinical trials evaluating molecules targeting AR may not predict response for ovarian cancer patients.</p>","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39852985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Apatinib Monotherapy as a Second-Line Treatment for Patients with Advanced Biliary Tract Cancer: a Retrospective Single-Center Observational Study","authors":"Yue Zhao, W. Gu, Jianmei Li, C. Tian","doi":"10.17303/jcrto.2019.7.205","DOIUrl":"https://doi.org/10.17303/jcrto.2019.7.205","url":null,"abstract":"Apatinib Monotherapy as a Second-Line Treatment for Patients with Advanced Biliary Tract Cancer: a Retrospective Single-Center Observational Study Yue Zhao1, #,*, Wenqian Gu2, #, Jianmei Li1, Chunyuan Tian1 1Department of Oncology, Qinhuangdao Fourth Hospital, 64 Guangming Rd, 066000, Hebei Province, China 2Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 165, 8200 Aarhus N, Denmark Research Open Access Journal of Cancer Research and Therapeutic Oncology","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79732798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Sugimoto, H. Kuroda, S. Yagyu, T. Gotoh, S. Osone, S. Tamura, T. Iehara, H. Hosoi
{"title":"Cellular and Molecular Characteristics of Established Neuroblastoma Cell Lines","authors":"T. Sugimoto, H. Kuroda, S. Yagyu, T. Gotoh, S. Osone, S. Tamura, T. Iehara, H. Hosoi","doi":"10.17303/jcrto.2019.7.201","DOIUrl":"https://doi.org/10.17303/jcrto.2019.7.201","url":null,"abstract":"1Shiga-ken Saiseikai Nursing School, Saiseikai Imperial Gift Foundation Inc, Ritto, Shiga, Japan 2Saiseikai Shiga Hospital, Saiseikai Imperial Gift Foundation Inc, Ritto, Shiga, Japan 3Department of Pediatrics, Kyoto Prefectual Univesity of Medicine, Kyoto, Japan 4Department of Pediatrics, University of Miyazaki, Miyazaki, Japan 5Department of Pediatrics, Kyoto City Hospital, Kyoto, Japan Review Open Access Journal of Cancer Research and Therapeutic Oncology","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72790725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Case Series of Therapeutic Outcomes of Head and Neck Cancer Patients with Unnoticed HIV Infection","authors":"A. Giotakis","doi":"10.17303/jcrto.2018.6.101","DOIUrl":"https://doi.org/10.17303/jcrto.2018.6.101","url":null,"abstract":"Background: Immune suppression secondary to Human Immunodeficiency Virus (HIV) infection is associated with an increased risk of head and neck cancer (HNC) and poorer tumor-related survival. In this article, the authors focused on the outcome of a specific subgroup of HIV-HNC patients with undetectable HIV load at cancer diagnosis. Case Presentation: We report of 4 HIV patients with head and neck cancer. The first patient showed an incidental finding of synchronous papillary thyroid carcinoma in the cervical lymph nodes after neck dissection. The second patient developed multiple local and regional recurrences of a nasal carcinoma. The third patient could not receive treatment for nasopharyngeal carcinoma due to multiple comorbidities. The fourth patient showed a long disease free survival after aggressive treatment of an oropharyngeal carcinoma. The patients reported developed synchronous HNC and local recurrences. Moreover, local control was not always easy to achieve. Multiple comorbidities, psychological factors and complications often led to treatment delay. Conclusions: The authors suggest consideration of early aggressive treatment and intensive follow up for HIV-HNC patients despite undetectable HIV load; since other parameters, such as immunosuppression, inflammation and direct viral oncogenic effect, could have already accelerate the natural course of the disease and affect the outcome.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"100 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90529215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Catheter Ablation Versus Antiarrhythmic Medication in Patients with Atrial Fibrillation: a Propensity-Matched Analysis Based on a German Claims Data Set","authors":"T. Wilke","doi":"10.17303/JCRTO.2019.5.203","DOIUrl":"https://doi.org/10.17303/JCRTO.2019.5.203","url":null,"abstract":"Aims: Main objective of our analysis was to assess the long-term clinical and health economics outcomes of catheter ablation versus antiarrhythmic medication therapy in Germany. Methods: We conducted a retrospective analysis of anonymized claims data covering the years 2010-2014. Patients with at least one diagnosis of AF and a minimum follow-up period of twelve months (excluding death) were included and assigned into two treatment groups: AF ablation and antiarrhythmic medication. To balance different patient characteristics in both groups, the final analysis was based on propensity score-matched (PSM) cohorts. Results: Of 498,253 AF patients, 2,404 could be assigned to the final analysis population – 1,202 patients in each group. The difference in the all-cause mortality rate reached statistical significance after 24 months of observation (1.5% versus 3.1% (p=0.015)) and after 36 months (1.7% versus 4.8% (p=0.005)). We could not identify any significant difference between the groups in cardiovascular events (amongst others stroke, TIA, myocardial infarction) over the three-year observation period. Direct cardiology-associated healthcare costs after index date (excluding catheter ablation procedure) were significantly different between the groups in the first and third observational year (third-year costs of €1,618 in the ablation group versus €2,462 in the medication group; p<0.007). Conclusion: Over a period of 36 months, all-cause mortality in AF patients who underwent catheter ablation was found to be significantly lower compared to AF patients who received antiarrhythmic medication. Direct cardiology healthcare costs after the ablation procedure proved to be consistently and significantly lower in comparison with medication therapy.","PeriodicalId":15189,"journal":{"name":"Journal of Cancer Research and Therapeutic Oncology","volume":"100 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75940442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}